
1. Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec
19.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N(1), Kuttruff-Coqui S(1), Frenzel K(2), Bukur V(2), Stevanović S(3)(4),
Gouttefangeas C(3)(4)(5), Platten M(6)(7)(8), Tabatabai G(3)(4)(9), Dutoit V(10),
van der Burg SH(5)(11), Thor Straten P(5)(12)(13), Martínez-Ricarte F(14),
Ponsati B(15), Okada H(16)(17), Lassen U(18), Admon A(19), Ottensmeier CH(20),
Ulges A(1), Kreiter S(2)(5), von Deimling A(6)(7), Skardelly M(9), Migliorini
D(10), Kroep JR(11), Idorn M(12)(13), Rodon J(14)(21), Piró J(15), Poulsen
HS(18), Shraibman B(19), McCann K(20), Mendrzyk R(1), Löwer M(2), Stieglbauer
M(3)(5), Britten CM(2)(5)(22), Capper D(6)(7)(23), Welters MJP(5)(11), Sahuquillo
J(14), Kiesel K(1), Derhovanessian E(2), Rusch E(3)(5), Bunse L(6)(7), Song C(1),
Heesch S(2), Wagner C(1), Kemmer-Brück A(2), Ludwig J(1), Castle JC(2)(24),
Schoor O(1), Tadmor AD(25), Green E(7)(8), Fritsche J(1), Meyer M(1), Pawlowski
N(1), Dorner S(1), Hoffgaard F(1), Rössler B(1), Maurer D(1), Weinschenk T(1),
Reinhardt C(1), Huber C(2), Rammensee HG(3)(4), Singh-Jasuja H(1), Sahin U(2),
Dietrich PY(10), Wick W(26)(27).

Author information: 
(1)Immatics Biotechnologies GmbH, Tübingen, Germany.
(2)BioNTech AG, Mainz, Germany.
(3)Eberhard Karls Universität Tübingen, Tübingen, Germany.
(4)German Cancer Consortium (DKTK), German Cancer Research Center Partner Site
Tübingen, Tübingen, Germany.
(5)CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer
Immunoguiding Program, Mainz, Germany.
(6)University Hospital Heidelberg, Heidelberg, Germany.
(7)German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg,
Germany.
(8)Medical Faculty Mannheim, Mannheim, Germany.
(9)University Hospital Tübingen, Tübingen, Germany.
(10)Geneva University Hospital, Geneva, Switzerland.
(11)Leiden University Medical Center, Leiden, The Netherlands.
(12)Center for Cancer Immune Therapy (CCIT), Department of Hematology, University
Hospital Herlev, Herlev, Denmark.
(13)Department of Immunology and Microbiology, University of Copenhagen,
Copenhagen, Denmark.
(14)Vall d'Hebron University Hospital, Barcelona, Spain.
(15)BCN Peptides SA, Barcelona, Spain.
(16)University of California, San Francisco, San Francisco, CA, USA.
(17)Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
(18)Ringhospitalet, Copenhagen, Denmark.
(19)Technion - Israel Institute of Technology, Haifa, Israel.
(20)University of Southampton, Southampton, UK.
(21)M. D. Anderson Cancer Center, University of Texas, Houston, TX, USA.
(22)Oncology R&D, GlaxoSmithKline, Stevenage, UK.
(23)Charité, University Medicine Berlin, Berlin, Germany.
(24)Agenus Inc., Lexington, KY, USA.
(25)TRON GmbH - Translational Oncology at the University Medical Center of
Johannes Gutenberg University, Mainz, Germany.
(26)University Hospital Heidelberg, Heidelberg, Germany.
wolfgang.wick@med.uni-heidelberg.de.
(27)German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg,
Germany. wolfgang.wick@med.uni-heidelberg.de.

Erratum in
    Nature. 2019 Feb;566(7745):E13.

Comment in
    Nature. 2019 Jan;565(7738):170-171.
    Nat Rev Neurol. 2019 Feb;15(2):59.
    Nat Rev Cancer. 2019 Mar;19(3):129.

Patients with glioblastoma currently do not sufficiently benefit from recent
breakthroughs in cancer treatment that use checkpoint inhibitors1,2. For
treatments using checkpoint inhibitors to be successful, a high mutational load
and responses to neoepitopes are thought to be essential3. There is limited
intratumoural infiltration of immune cells4 in glioblastoma and these tumours
contain only 30-50 non-synonymous mutations5. Exploitation of the full repertoire
of tumour antigens-that is, both unmutated antigens and neoepitopes-may offer
more effective immunotherapies, especially for tumours with a low mutational
load. Here, in the phase I trial GAPVAC-101 of the Glioma Actively Personalized
Vaccine Consortium (GAPVAC), we integrated highly individualized vaccinations
with both types of tumour antigens into standard care to optimally exploit the
limited target space for patients with newly diagnosed glioblastoma. Fifteen
patients with glioblastomas positive for human leukocyte antigen (HLA)-A*02:01 or
HLA-A*24:02 were treated with a vaccine (APVAC1) derived from a premanufactured
library of unmutated antigens followed by treatment with APVAC2, which
preferentially targeted neoepitopes. Personalization was based on mutations and
analyses of the transcriptomes and immunopeptidomes of the individual tumours.
The GAPVAC approach was feasible and vaccines that had poly-ICLC
(polyriboinosinic-polyribocytidylic acid-poly-L-lysine carboxymethylcellulose)
and granulocyte-macrophage colony-stimulating factor as adjuvants displayed
favourable safety and strong immunogenicity. Unmutated APVAC1 antigens elicited
sustained responses of central memory CD8+ T cells. APVAC2 induced
predominantly CD4+ T cell responses of T helper 1 type against predicted
neoepitopes.

DOI: 10.1038/s41586-018-0810-y 
PMID: 30568303  [Indexed for MEDLINE]

